BILL ANALYSIS

S4106

BEARISH

A bill to amend title 10, United States Code, to improve access to certain medications under the TRICARE program, and for other purposes.

S4106 (A bill to amend title 10, United States Code, to improve access to certain medications under the TRICARE program, and for other purposes.) has been assessed with a bearish outlook for investors. The primary sectors impacted are Healthcare. View the full bill text on Congress.gov.

bearish

Market Sentiment

4/10

Impact Score

Sectors Impacted

Key Takeaways for Investors

S.4106 (Rx ACCESS Act) would change TRICARE pharmacy rules, benefiting retail pharmacies and pressuring PBMs.

The bill is in committee with bipartisan support and a House companion, but early stage limits near-term impact.

Market impact is moderate and concentrated in $WBA (bullish) and $CI (bearish).

How S4106 Affects the Market

The bill introduces regulatory changes to TRICARE's pharmacy benefit that directly affect two company types: retail pharmacies (Walgreens, ) and pharmacy benefit managers (Cigna, $CI). For , the mandated cost-plus reimbursement could improve margins on a small but recurring revenue stream. For $CI, the loss of spread revenue on TRICARE prescriptions could reduce segment profitability. However, given the small scale of TRICARE relative to these companies' total operations, the stock-level impact is likely muted unless the bill signals broader PBM reform. Investors should watch for movement out of committee and any amendments that expand the scope.

Bill Details

Metric	Value
Bill Number	S4106
Market Sentiment	bearish
Event Date	April 13, 2026
Affected Sectors	Healthcare
Source	View on Congress.gov →

Summary

S.4106 (Rx ACCESS Act) would change TRICARE pharmacy rules, allowing beneficiaries to get non-generic maintenance drugs at retail pharmacies and mandating cost-based PBM reimbursement. The bill is in early committee stage with bipartisan support. It would modestly benefit retail pharmacies like $WBA and pressure PBMs like $CI.

⚡ Government Convergence

VA / Government Health ITConvergence score 64 · 3 channels · 32 events

Over the last 90 days, 32 separate government actions have converged on VA / Government Health IT. What that means: federal dollars are already moving — agencies are soliciting bids and awarding contracts, not just talking, and legislation and executive action are building the policy and funding tailwind behind it. When independent channels move together like this — 27 federal contracts, 4 bills and 1 procurement notices — it's the clearest early tell that Washington is committing to va / government health it, the kind of build-up that reshapes the sector well before it's obvious in the headlines.

Converging government actions

ContractTRIWEST HEALTHCARE ALLIANCE CORP: $984M Department of Veterans Affairs Contract · 2026-08-03
ContractOPTUM PUBLIC SECTOR SOLUTIONS, INC.: $668M Department of Veterans Affairs Contract · 2026-07-31
ContractOPTUM PUBLIC SECTOR SOLUTIONS, INC.: $621M Department of Veterans Affairs Contract · 2026-07-31
ContractOPTUM PUBLIC SECTOR SOLUTIONS, INC.: $628M Department of Veterans Affairs Contract · 2026-07-31
ContractOPTUM PUBLIC SECTOR SOLUTIONS, INC.: $962M Department of Veterans Affairs Contract · 2026-07-31
ContractOPTUM PUBLIC SECTOR SOLUTIONS, INC.: $918M Department of Veterans Affairs Contract · 2026-07-31
ContractOPTUM PUBLIC SECTOR SOLUTIONS, INC.: $919M Department of Veterans Affairs Contract · 2026-07-31
ContractOPTUM PUBLIC SECTOR SOLUTIONS, INC.: $706M Department of Veterans Affairs Contract · 2026-07-31

Full AI Market Analysis

S.4106, introduced in March 2026 by Sen. Cotton (R-AR) with five bipartisan cosponsors, is currently in the Senate Armed Services Committee. A companion bill (HR6400) exists in the House. The bill amends TRICARE pharmacy benefits to allow beneficiary choice of retail pharmacy for non-generic maintenance medications starting October 2026, and imposes reimbursement standards requiring the PBM contractor (Express Scripts, owned by Cigna) to pay retail pharmacies at least acquisition cost plus a dispensing fee. This is an authorization bill with no direct appropriations; it sets policy for the TRICARE program. The primary market impact is on pharmacy benefit managers (PBMs) and retail pharmacies. For PBMs like Cigna's Express Scripts, the mandated reimbursement formula reduces their ability to profit from the spread between what they pay pharmacies and what they charge the government. For retail pharmacies like Walgreens, the bill guarantees a minimum reimbursement, improving margins on TRICARE prescriptions. However, TRICARE covers only about 9.5 million beneficiaries, so the overall financial impact is small relative to these companies' total revenues. The legislative path is early but has bipartisan backing; passage is uncertain but possible within the 119th Congress. Structural winners are retail pharmacy chains; losers are PBMs with TRICARE contracts.